ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection |
| |
| Authors: | Pragya D Yadav Sanjeev Kumar Mendiratta Sreelekshmy Mohandas Arun K Singh Priya Abraham Anita Shete Sanjay Bandyopadhyay Sanjay Kumar Aashini Parikh Pankaj Kalita Vibhuti Sharma Hardik Pandya Chirag G Patel Mihir Patel Swagat Soni Suresh Giri Mukul Jain |
| |
| Institution: | 1.Indian Council of Medical Research-National Institute of Virology, Pune 411021, India; (S.M.); (P.A.); (A.S.);2.Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India; (S.K.M.); (A.K.S.); (S.B.); (A.P.); (P.K.); (V.S.); (H.P.); (C.G.P.); (M.P.); (S.S.); (S.G.); (M.J.);3.Department of Neurosurgery, Command Hospital (Southern Command), Armed Forces Medical College (AFMC), Pune 411040, India; |
| |
| Abstract: | We have developed a monoclonal antibody (mAb) cocktail (ZRC-3308) comprising of ZRC3308-A7 and ZRC3308-B10 in the ratio 1:1 for COVID-19 treatment. The mAbs were designed to have reduced immune effector functions and increased circulation half-life. mAbs showed good binding affinities to non-competing epitopes on RBD of SARS-CoV-2 spike protein and were found neutralizing SARS-CoV-2 variants B.1, B.1.1.7, B.1.351, B.1.617.2, and B.1.617.2 AY.1 in vitro. The mAb cocktail demonstrated effective prophylactic and therapeutic activity against SARS-CoV-2 infection in Syrian hamsters. The antibody cocktail appears to be a promising candidate for prophylactic use and for therapy in early COVID-19 cases that have not progressed to severe disease. |
| |
| Keywords: | ZRC3308 SARS-CoV-2 monoclonal antibody prophylaxis hamsters |
|
|
